Required for US and Japanese stocks. A-shares and HK stocks work without a key.
DeepSeek R1 provides high-quality analysis at very low cost. Serper provides real-time search data for context.
BioDlink International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat metastatic colorectal cancer; advanced, metastatic or recurrent non-small cell lung cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer; fallopian tube cancer or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatment of glioblastoma and anaplastic astrocytoma. In addition, the company develops TAB014 a bevacizumab ophthalmic drug for the treatment of wet age-related macular degeneration (wAMD). Further, it engages in contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business; license-out of self-developed biological drugs; and business development, investing, and marketing promotion activities. The company was formerly known as TOT BIOPHARM International Company Limited and changed its name to BioDlink International Company Limited in July 2025. BioDlink International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China. BioDlink International Company Limited operates as a subsidiary of WuXi XDC Cayman Inc.
交易所：HKG。行业板块：Healthcare。细分行业：Biotechnology。最新股价：HK$3.6。本页提供 BioDlink International Company Limited 的 DCF 现金流折现估值、相对估值历史分位、多维财务评分与 AI 辅助分析。
Required for US and Japanese stocks. A-shares and HK stocks work without a key.
DeepSeek R1 provides high-quality analysis at very low cost. Serper provides real-time search data for context.